Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $8.25 per share versus the Zacks Consensus Estimate of a loss of $6.12. This compares to earnings of $5.3 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -34.80%. A quarter ago, it was expected that this drugmaker would post earnings of $4.51 per share when it actually produced earnings of $1.68, delivering a surprise of -62.75%. Over the last four quarters, the co ...